论文部分内容阅读
目的探讨加巴喷丁(GBP)对糖尿病神经痛(PDN)患者血浆β内啡肽(β-EP)水平的影响。方法 42例PDN患者按是否服用GBP分为GBP组24例与PDN对照组18例,糖尿病无神经痛患者20例为DM组,成年健康体检者24例为正常对照(NC)组。测定各组研究对象血浆β-EP含量。结果 (1)糖尿病各组血浆β-EP的含量低于NC组(P<0.01)。(2)GBP组治疗后β-EP含量较治疗前下降(P<0.01),PDN对照组治疗前后β-EP水平无统计学差异。结论加巴喷丁治疗糖尿病神经痛效果确切,副作用轻,可降低-EP。
Objective To investigate the effect of gabapentin (β-EP) on the level of β-endorphin (β-EP) in patients with diabetic neuropathic pain (PDN). Methods Twenty-four PDN patients were divided into GBP group (24 cases) and PDN control group (18 cases). Diabetic patients without neuropathic pain (20 cases) were DM group, and adult healthy subjects (24 cases) were normal control group (NC). Plasma β-EP levels were determined in each group. Results (1) The content of plasma beta-EP in diabetic group was lower than that in NC group (P <0.01). (2) The content of β-EP decreased in GBP group before treatment (P <0.01), but there was no significant difference in β-EP level before and after treatment in GBP group. Conclusion Gabapentin is effective in treating diabetic neuropathic pain with mild side effects and can reduce -EP.